Delpazolid
Appearance
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H17FN4O3 |
| Molar mass | 308.313 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Delpazolid (LCB01-0371) is an experimental antibiotic drug for the treatment of tuberculosis.[1][2]
References
[edit]- ↑ Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, et al. (February 2022). "Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis". Antimicrobial Agents and Chemotherapy. 66 (2): e0168421. doi:10.1128/AAC.01684-21. PMC 8846473. PMID 34871098.
- ↑ Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, et al. (June 2023). "A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis". Trials. 24 (1): 382. doi:10.1186/s13063-023-07354-5. PMC 10243693. PMID 37280643.